We operate from a purpose-built 65,000ft² (6,000m²) GMP facility in Bristol, designed to support cell and gene therapy developers from early-stage clinical programmes through to commercial manufacture. Our facility includes fully qualified Grade C cleanrooms, integrated fill-finish capability, QC labs, GMP warehousing, and 12,000ft² of expansion space for additional clinical, pivotal, or commercial manufacturing capacity.
Apr 11, 2025
What is our scale of operation?
We operate from a purpose-built 65,000ft² (6,000m²) GMP facility in Bristol, designed to support cell and gene therapy developers from early-stage clinical programmes through to commercial manufacture. Our facility includes fully qualified Grade C cleanrooms, integrated fill-finish capability, QC labs, GMP warehousing, and 12,000ft² of expansion space for additional clinical, pivotal, or commercial manufacturing capacity.
Latest News
eXmoor Pharma and Signadori Bio launch partnership to develop next-generation monocyte-based cell therapy for solid tumours
Jun 17, 2025
Scaling Gene Therapy Production: From Bench to Clinic
May 30, 2025
eXmoor Pharma and KU Leuven announce strategic partnership to accelerate cell and gene therapy innovation through new venture
May 13, 2025
Let’s Accelerate Your Therapy Together
Whether you're in early-stage development or scaling up for commercial production, eXmoor Pharma provides the expertise and flexibility you need. Partner with us to move your therapy forward with confidence.